AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 2 - (NewsRx.com & NewsRx.net) -- Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.
"For evaluation of serum bactericidal activity (SBA) as surrogate for the efficacy of outer membrane vesicle (OMV) vaccines against Neisseria meningitidis serogroup B disease, we have reanalyzed data from a randomized double blind placebo-controlled efficacy trial involving 172,000 secondary school students (aged 13-14 years) in Norway (1988-1991). A cohort of the efficacy trial consisting of 880 individuals was selected for immunogenicity studies," researchers in Norway report.
"An efficacy of 87% was calculated for a 10-month observation period," said J. Holst and colleagues at the Norwegian Institute of Public Health. "However, after an observation period of 29 months, the estimated efficacy against group B disease induced by vaccination was 57%. The immunogenicity study showed that the SBA geometric mean titer (GMT) for the vaccinees was 2.4 before vaccination and 19.0 six weeks after the second vaccine dose. One year after vaccination the GMT was reduced to 2.8."
"A separate three-dose study with 304 adolescents showed that with a third dose at 10 months after the second dose (i.e., when cases of disease started to appear) a strong booster response was induced," the investigators stated. "Ten months after the second dose the SBA was reduced to near pre-immunization level. ...
Source: HighBeam Research, Bactericidal activity correlates with N. meningitidis vaccine...